6 erythematosus,” Postgraduate Medical Journal, vol. 80, no. 944, pp. 366–367, 2004. [6] American College of Rheumatology, “1997 Update of the 1982 American College of Rheumatology Revised Criteria for Classiﬁcation of Systemic Lupus Erythematosus,” http://www.rheumatology.org/practice/clinical/classiﬁcation/ SLE/1997 update of the 1982 acr revised criteria for classiﬁcation of sle.pdf. [7] A. Tincani, C. B. Rebaioli, M. Taglietti, and Y. Shoenfeld, “Heart involvement in systemic lupus erythematosus, anti- phospholipid syndrome and neonatal lupus,” Rheumatology, vol. 45, supplement 4, pp. iv8–iv13, 2006. [8] D. Jain and M. K. Halushka, “Cardiac pathology of systemic lupus erythematosus,” Journal of Clinical Pathology, vol. 62, no. 7, pp. 584–592, 2009. [9] M. R. Hejtmancik, J. C. Wright, R. Quint, and F. L. Jennings, “The cardiovascular manifestations of systemic lupus erythe- matosus,” American Heart Journal, vol. 68, no. 1, pp. 119–130, 1964. [10] A. Doria, L. Iaccarino, P. Sarzi-Puttini, F. Atzeni, M. Turriel, and M. Petri, “Cardiac involvement in systemic lupus erythe- matosus,” Lupus, vol. 14, no. 9, pp. 683–686, 2005. [11] M. Hojnik, J. George, L. Ziporen, and Y. Shoenfeld, “Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome,” Circulation, vol. 93, no. 8, pp. 1579–1587, 1996. [12] J. E. Salmon and M. J. Roman, “Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management,” Current Opinion in Rheumatology, vol. 13, no. 5, pp. 341–344, 2001. [13] S. Manzi, E. N. Meilahn, J. E. Rairie et al., “Age-speciﬁc incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study,” American Journal of Epidemiology, vol. 145, no. 5, pp. 408–415, 1997. [14] M. Nikpour, M. B. Urowitz, D. Ibanez, and D. D. Gladman, “Relationship between cardiac symptoms, myocardial perfu- sion defects and coronary angiography ﬁndings in systemic lupus erythematosus,” Lupus. In press. [15] Y. H. Rho, C. P. Chung, A. Oeser et al., “Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus,” Journal of Rheumatology, vol. 35, no. 9, pp. 1789–1794, 2008. [16] S. Codish, N. Liel-Cohen, M. Rovner, S. Sukenik, and M. Abu- Shakra, “Dobutamine stress echocardiography in women with systemic lupus erythematosus: increased occurrence of left ventricular outﬂow gradient,” Lupus, vol. 13, no. 2, pp. 101– 104, 2004. [17] J. A. Singh, P. K. Woodard, V. G. Da´vila-Roma´n et al., “Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report,” Lupus, vol. 14, no. 2, pp. 137–144, 2005. [18] M. J. Fairfax, T. G. Osborn, G. A. Williams, C. C. Tsai, and T. L. Moore, “Endomyocardial biopsy in patients with systemic lupus erythematosus,” Journal of Rheumatology, vol. 15, no. 4, pp. 593–596, 1988. [19] W. G. Law, B. Y. Thong, T. Y. Lian, K. O. Kong, and H. H. Chng, “Acute lupus myocarditis: clinical features and outcome of an oriental case series,” Lupus, vol. 14, no. 10, pp. 827–831, 2005. [20] J. W. Chung, D. Y. Joe, H. J. Park, H. A. Kim, H. S. Park, and C. H. Suh, “Clinical characteristics of lupus myocarditis in Korea,” Rheumatology International, vol. 28, no. 3, pp. 275– 280, 2008. Cardiology Research and Practice [21] Y. Sherer, Y. Levy, and Y. Shoenfeld, “Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythemato- sus,” Clinical Rheumatology, vol. 18, no. 3, pp. 238–240, 1999. [22] I. H. Tarner, U. Lange, K. Madlener et al., “A wolf in sheep’s clothing: atypical systemic lupus erythematosus (SLE) presenting as cardiovascular disease,” Medizinische Klinik, vol. 105, no. 4, pp. 300–304, 2010. [23] M. Lockshin, F. Tenedios, M. Petri et al., “Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report,” Lupus, vol. 12, no. 7, pp. 518–523, 2003. [24] P. M. Seferovic´, A. D. Ristic´, R. Maksimovic´ et al., “Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases,” Rheumatology, vol. 45, supplement 4, pp. iv39–iv42, 2006. [25] M. Peregud-Pogorzelska, J. Kaz´mierczak, and Z. Kornacewicz- Jach, “Heart failure in systemic lupus erythematosus treated by cardiac resynchronization: a case report,” Angiology, vol. 58, no. 2, pp. 238–241, 2007. [26] P. E. Vardas, A. Auricchio, J. J. Blanc et al., “Guidelines for cardiac pacing and cardiac resynchronization therapy: the Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association,” European Heart Journal, vol. 28, no. 18, pp. 2256–2295, 2007. [27] G. N. Theodorakis, P. Flevari, C. Kroupis et al., “Anti- inﬂammatory eﬀects of cardiac resynchronization therapy in patients with chronic heart failure,” Pacing and Clinical Electrophysiology, vol. 29, no. 3, pp. 255–261, 2006. [28] T. C. Pulerwitz, T. P. Cappola, G. M. Felker, J. M. Hare, K. L. Baughman, and E. K. Kasper, “Mortality in primary and secondary myocarditis,” American Heart Journal, vol. 147, no. 4, pp. 746–750, 2004. [29] A. Colli, C. A. Mestres, G. Espinosa et al., “Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases,” European Journal of Cardio-thoracic Surgery, vol. 37, no. 1, pp. 154–158, 2010. [30] N. Tweezer-Zaks, G. Zandman-Goddard, M. Lidar, Y. Har- Zahav, A. Livneh, and P. Langevitz, “A long-term follow-up after cardiac transplantation in a lupus patient: case report and review of the literature,” Annals of the New York Academy of Sciences, vol. 1110, pp. 539–543, 2007. [31] R. D. Levy, A. J. Guerraty, M. H. Yacoub, and R. Loertscher, “Prolonged survival after heart-lung transplantation in sys- temic lupus erythematosus,” Chest, vol. 104, no. 6, pp. 1903– 1905, 1993.